Danielle Mercatante Carrick, Ph.D., M.H.S.
Program Director, Host Susceptibility Factors Branch
- Telephone: (240) 276-6749
- Fax: (240) 276-7921
- E-mail: email@example.com
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E224, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Immunology, infectious diseases, and autoimmune diseases associated with cancer risk
- Pharmacoepidemiology and pharmacogenomics in relation to cancer risk
- Biospecimen research
- Translational medicine
- Ph.D. - Pharmacology
University of North Carolina at Chapel Hill
- M.H.S. - Clinical Research
- B.S. - Biology
University of Richmond
Dr. Danielle Mercatante Carrick is a Program Director in the Host Susceptibility Factors Branch (HSFB). She is responsible for managing a research grant portfolio related to genetic and immunologic factors that influence personal susceptibility to cancer.
Dr. Carrick has worked for more than 14 years as a molecular pharmacologist and clinical researcher with experience conducting epidemiological, biomedical, genetic, and pharmacological research studies with a focus on cancer, biospecimen science, autoimmune diseases, infectious diseases, immunology, and transfusion medicine. Prior to joining EGRP, she worked for seven years at Westat, Inc., serving as Co-Deputy Project Director and Biospecimen Lead for the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and Epidemiologist for the National Heart, Lung, and Blood Institute's Retrovirus Epidemiology Donor Study II (REDS-II).
Dr. Carrick completed her post-doctoral training as an Intramural Research Training Award (IRTA) Fellow in the Office of Clinical Research at the National Institute of Environmental Health Sciences (NIEHS). She conducted studies to examine potential genetic associations with cancer, autoimmune disorders, asthma, and congenital hydrocephalus and to develop laboratory tests that measured immune regulator gene expression levels in whole blood and monocytes in response to environmental factors. While at NIEHS, Dr. Carrick was selected to receive training in epidemiology through the NIH-Duke Training Program in Clinical Research.
Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, Tobler LH, Carrick DM, Steele W, Todd D, Wright DJ, Kleinman SH, Busch MP; NHLBI-REDS-II Study Group. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis. 2012 Mar 15;205(6):875-85.
Kleinman SH, Triulzi DJ, Murphy EL, Carey PM, Gottschall JL, Roback JD, Carrick D, Mathew S, Wright DJ, Cable R, Ness P, Gajic O, Hubmayr RD, Looney MR, Kakaiya RM; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components. Transfusion. 2011 Oct;51(10):2078-91.
Carrick DM, Norris PJ, Endres RO, Pandey S, Kleinman SH, Wright D, Sun Y, Busch MP; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion. 2011 Oct;51(10):2092-101.
Carrick DM, Blackshear PJ. Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys. 2007 Jun 15;462(2):278-85.
Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun. 2006 May;26(3):182-96.